Several previous studies have demonstrated the influence of GATA2 expression levels on the clinical outcome in patients with pediatric acute myeloid leukemia (AML), colorectal, prostate, breast cancer, and hepatocellular carcinoma [14, 16–20]. Here, GATA2 is linked to hepatocellular carcinoma.